Protein-Based Predictive Biomarkers to Personalize Neoadjuvant Therapy for Bladder Cancer—A Systematic Review of the Current Status
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(18), С. 9899 - 9899
Опубликована: Сен. 13, 2024
The
clinical
outcome
of
patients
with
muscle-invasive
bladder
cancer
(MIBC)
is
poor
despite
the
approval
neoadjuvant
chemotherapy
or
immunotherapy
to
improve
overall
survival
after
cystectomy.
MIBC
subtypes,
immune,
transcriptome,
metabolomic
signatures,
and
mutation
burden
have
potential
predict
treatment
response
but
none
been
incorporated
into
practice,
as
tumor
heterogeneity
lineage
plasticity
influence
their
efficacy.
Using
PRISMA
statement,
we
conducted
a
systematic
review
literature,
involving
135
studies
published
within
last
five
years,
identify
reporting
on
prognostic
value
protein-based
biomarkers
for
therapy
in
MIBC.
were
grouped
based
related
molecular
stem
cell,
actin-cytoskeleton,
epithelial–mesenchymal
transition,
apoptosis,
tumor-infiltrating
immune
cells.
These
show
biomarkers,
especially
spatial
context,
reduce
biomarker’s
capability.
Nevertheless,
currently,
there
little
consensus
methodology,
reagents,
scoring
systems
allow
reliable
assessment
interest.
Furthermore,
small
sample
size
several
necessitates
validation
larger
multicenter
cohorts
before
use
individualizing
regimens
Язык: Английский
CTLA4 genetic variants associated with urothelial bladder cancer susceptibility
Urologic Oncology Seminars and Original Investigations,
Год журнала:
2024,
Номер
42(11), С. 374.e1 - 374.e10
Опубликована: Июнь 15, 2024
Язык: Английский
Identification of a circadian-based prognostic signature predicting cancer-associated fibroblasts infiltration and immunotherapy response in bladder cancer
Aging,
Год журнала:
2024,
Номер
unknown
Опубликована: Авг. 30, 2024
Circadian
rhythm
disruption
impacts
the
efficiency
of
both
chemotherapy
and
immunotherapy,
yet
identifying
key
factors
involved
remains
challenging.
can
trigger
aberrant
fibroblasts
activation,
suggesting
potential
roles
cancer-associated
(CAFs)
in
addressing
this
issue.
In
paper,
TCGA-BLCA
patients
were
classified
into
two
subgroups
based
on
expression
core
circadian
genes
(CCRGs).
The
CCRG-based
showed
distinct
fibroblast-related
signals,
from
which
a
risk
model
composed
five
was
finally
established
with
excellent
survival
prognostic
value
TCGA
GEO
datasets.
positively
associated
infiltration
CAFs
efficiently
predict
immunotherapy
response
BLCA.
Besides,
high-risk
score
reduced
sensitivity
to
majority
traditional
chemotherapeutic
drugs
such
as
oxaliplatin
gemcitabine.
Further,
correlation
between
CCRGs
analyzed.
Among
genes,
Язык: Английский
Contemporary Molecular Markers for Predicting Systemic Treatment Response in Urothelial Bladder Cancer: A Narrative Review
Cancers,
Год журнала:
2024,
Номер
16(17), С. 3056 - 3056
Опубликована: Сен. 1, 2024
The
search
for
dependable
molecular
biomarkers
to
enhance
routine
clinical
practice
is
a
compelling
challenge
across
all
oncology
fields.
Urothelial
bladder
carcinoma,
known
its
significant
heterogeneity,
presents
difficulties
in
predicting
responses
systemic
therapies
and
outcomes
post-radical
cystectomy.
Recent
advancements
cancer
biology
offer
promising
avenues
understand
the
disease's
identify
emerging
predictive
biomarkers.
Stratifying
patients
based
on
their
recurrence
risk
post-curative
treatment
or
efficacy
of
conventional
targeted
could
catalyze
personalized
selection
disease
surveillance.
Despite
progress,
reliable
forecast
agents,
neoadjuvant,
adjuvant,
palliative
settings,
are
still
lacking,
underscoring
an
urgent
unmet
need.
This
review
aims
delve
into
utilization
current
signatures
various
stages
urothelial
carcinoma
predict
therapy.
Язык: Английский
Role of Neoadjuvant Immunotherapy in Genitourinary Malignancies
Cancers,
Год журнала:
2024,
Номер
16(24), С. 4127 - 4127
Опубликована: Дек. 10, 2024
Genitourinary
(GU)
malignancies
are
common
and
associated
with
significant
morbidity
mortality.
In
patients
localized
GU
cancers,
surgical
resection
or
definitive
radiation
remain
the
mainstays
of
treatment.
Despite
treatment,
many
high-risk
disease
experience
recurrence.
There
is
growing
interest
in
using
neoadjuvant
immunotherapy
to
improve
outcomes.
This
narrative
review
summarizes
current
evidence
for
cancers
including
renal
cell
carcinoma,
urothelial
prostate
cancer,
penile
squamous
testicular
germ
tumors.
We
also
discuss
ongoing
clinical
trials
candidate
biomarkers
optimize
patient
selection
treatment
Язык: Английский